Answers are grounded in this paper and cite their sources.
Jokūbas Leikauskas, Editor, Nucleic Acid Insights, speaks with Edward Miracco, Head of Enterprise AI Enablement, Moderna, about enterprise AI adoption, AI-driven lipid nanoparticle and neoantigen design, rare disease applications of mRNA, and the future of RNA therapeutics.
No takes yet. Share an insight, caveat, or question.
Edward Miracco (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: